Eupraxia Pharmaceuticals Inc (EPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -38,606 | -25,745 | -28,966 | -18,991 |
| Depreciation Amortization | 238 | 172 | 156 | 148 |
| Accounts receivable | -431 | -101 | -104 | 231 |
| Other Working Capital | -714 | -6,765 | 5,352 | 1,515 |
| Other Operating Activity | 10,961 | 2,444 | 2,814 | 2,703 |
| Operating Cash Flow | $-28,552 | $-29,995 | $-20,749 | $-14,395 |
| Cash Flows From Investing Activities | ||||
| Change In Deposits | N/A | N/A | N/A | 10,070 |
| PPE Investments | -589 | -75 | -73 | -235 |
| Investing Cash Flow | $-589 | $-75 | $-73 | $9,834 |
| Cash Flows From Financing Activities | ||||
| Debt Repayment | N/A | -9,075 | N/A | N/A |
| Common Stock Issued | 2,167 | 363 | 5,272 | 307 |
| Other Financing Activity | 73,891 | 54,496 | 15,807 | 10,494 |
| Financing Cash Flow | $76,059 | $45,784 | $21,079 | $10,801 |
| Exchange Rate Effect | 545 | -1,955 | 821 | -507 |
| Beginning Cash Position | 33,101 | 19,342 | 18,263 | 12,531 |
| End Cash Position | 80,564 | 33,101 | 19,342 | 18,263 |
| Net Cash Flow | $47,462 | $13,760 | $1,078 | $5,733 |
| Free Cash Flow | ||||
| Operating Cash Flow | -28,552 | -29,995 | -20,749 | -14,395 |
| Capital Expenditure | -589 | -104 | -73 | -236 |
| Free Cash Flow | -29,141 | -30,099 | -20,822 | -14,631 |